Medical Compression Systems Ltd. Expands U.S. Operations and Appoints Industry Veteran to Newly Created Role of President
Published: Mar 10, 2010
"We are thrilled to welcome Ambaw to our team. Ambaw brings significant experience to a role that signifies a strategic addition to our management team, and is a further indicator of our commitment to growing our presence in the U.S. market," said Adi Dagan, chief executive officer, Medical Compression Systems. "Ambaw's vast and impressive experience as vice president at Sanofi Aventis, leading the commercial efforts of Lovenox and other deep vein thrombosis prevention medications such as Arixtra(R) and Fragmin(R), will add critical value to MCS as we grow and significantly expand efforts around our mobile compression device, ActiveCare+S.F.T., for the prevention of venous thromboembolism following surgery."
This appointment follows the recent publication of results from the landmark head-to-head S.A.F.E. (S.F.T. Alternative to Enoxaparin) study in the March 2010 issue of Journal of Bone and Joint Surgery, demonstrating that the ActiveCare+S.F.T non-invasive mobile compression system, used as monotherapy, achieved no significant difference in efficacy and a significant decrease in major bleeding events compared to Lovenox (enoxaparin sodium injection) in the prevention of venous thromboembolism (VTE) in total hip arthroplasty (THA).
"As a non-invasive, non-pharmaceutical solution that not only demonstrates excellent efficacy, but also provides important safety features including eliminating the concerns about bleeding and drug-drug interactions associated with traditional pharmacologic approaches, the novel ActiveCare+S.F.T. system represents a much-needed advance in how VTE prevention should be safely managed," said Ambaw Bellete, president, U.S., Medical Compression Systems, Inc. "I am pleased to join the MCS team at such an exciting time in the company's growth, and look forward to further building our presence in the U.S. through expanded commercialization of ActiveCare+S.F.T."
The ActiveCare+S.F.T. system is the first non-invasive, medical device clinically proven to prevent VTE in total hip arthroplasty throughout the time of high risk (approximately 10 days post-operation, including in and outpatient terms). The system generates a unique venous flow in the limbs that is highly efficacious in preventing VTEs. It is also palm-sized and mobile, thus promoting high patient compliance in and out of the hospital.
MCS will showcase the novel ActiveCare+S.F.T. device, and provide educational information regarding the recent publication of the S.A.F.E. study, this week at the American Academy of Orthopaedic Surgeons (AAOS) 77th Annual Meeting, booth #437, in New Orleans, Louisiana.
About Deep Vein Thrombosis and Venous Thromboembolism
Deep vein thrombosis (DVT) is a serious, potentially life-threatening condition in which a blood clot (thrombus) forms in one or more of the deep veins in the lower limbs (legs). Left untreated, these clots can cause disability or become life threatening; the clot can break off, travel through the bloodstream and restrict blood flow in the lungs, causing a pulmonary embolism (PE). Venous thromboembolism (VTE) is the collective term for DVT and PE. Without preventative treatment, the rate of DVT after THA is as high as 50 percent. According to the American Heart Association, more than 200,000 new cases of PE occur annually in the United States. Of these, 30 percent die within 30 days, one-fifth suffers sudden death due to PE, and about 30 percent develop recurrent VTE within 10 years. Independent predictors for recurrence include increasing age, obesity, malignant neoplasm and extremity paresis.
About ActiveCare+S.F.T.(R) Continuous Enhanced Circulation Therapy(R) System
The ActiveCare+S.F.T.(R) Continuous Enhanced Circulation Therapy(R) (C.E.C.T) system is the first non-invasive, non-pharmaceutical monotherapy clinically proven to prevent venous thromboembolism (VTE) in total hip arthroplasty. ActiveCare+S.F.T. uniquely improves the blood circulation in the limbs with a palm-sized, mobile, pneumatic compression therapy system.
The system works by gently applying compression to your legs, increasing the speed of blood flow in the veins and reducing the risk of clot formation. Its portable size, lightweight mobility and ease of use provides patients with protection for the most safe and effective way to prevent deep vein thrombosis (DVT). The system shows high compliance with patients, and is able to deliver its unique therapy on a continual basis both in and out of the hospital, without the use of anticoagulants and their associated bleeding risks.
About Medical Compression Systems (MCS)
MCS is a leader in the field of non-invasive blood circulation solutions through a pneumatic device. The company has developed a device to prevent Deep Vein Thrombosis (DVT) as a result of trauma or surgical intervention. MCS is the first company to offer the international medical market a non-invasive blood circulation solution that can replace the medication therapy that is currently the standard treatment. The company's technologies and product lines are protected by numerous patents and are internationally certified with FDA and CE approvals.
Founded in 1997, MCS is an Israeli public company, traded on the Tel Aviv Stock Exchange (TASE: MDCL). The company's management and R&D are headquartered in Israel with manufacturing facilities located in both Israel and the U.S. The company's sales and marketing teams are managed in the U.S. by its subsidiary, MCS Inc., which conducts in-depth training and support programs to distributors and medical facilities throughout the country. For more information on MCS, visit Medical Compression Systems online at: www.mcsmed.com.
SOURCE: Medical Compression Systems, Ltd.
Medical Compression Systems, Inc. Mark Sacaris, Vice President, Marketing, 858-345-1156 www.mcsmed.comor Pure Communications Dan Budwick, 973-271-6085
Copyright Business Wire 2010